Galmed Pharmaceuticals Ltd. (GLMD) has a negative trailing P/E of -0.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -174.04%.
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -28.2 | -0.51 | 43.24 | 1,025.39 | - |
| 2017 | -114.3 | 3.37 | 89.04 | 1,296.19 | - |
| 2018 | -150.8 | 3.36 | 16.90 | 729.06 | - |
| 2019 | -78.9 | -1.28 | 20.95 | 0.00 | - |
| 2020 | -28.8 | -0.60 | 17.98 | 0.00 | - |
| 2021 | -16.8 | -163.53 | 17.61 | 0.00 | - |
| 2022 | -8.1 | 0.19 | 11.23 | 0.00 | - |
| 2023 | -0.2 | 0.00 | 0.09 | 0.00 | - |
| 2024 | -0.4 | 0.01 | 0.18 | 0.00 | - |
| 2025 | -0.3 | 0.00 | 0.21 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2015 | $-14.35 | $0.00 | $-10.62M | - |
| 2016 | $-22.36 | $467K | $-16.95M | -3630.2% |
| 2017 | $-14.77 | $1.09M | $-12.3M | -1133.5% |
| 2018 | $-8.15 | $2.04M | $-9.86M | -483.6% |
| 2019 | $-13.17 | $0.00 | $-18.54M | - |
| 2020 | $-19.46 | $0.00 | $-27.61M | - |
| 2021 | $-19.48 | $0.00 | $-31.95M | - |
| 2022 | $-11.08 | $0.00 | $-18.57M | - |
| 2023 | $-29.95 | $0.00 | $-6.91M | - |
| 2024 | $-8.08 | $0.00 | $-7.52M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.85 | $-0.85 – $-0.85 | $5.72M | $5.72M – $5.72M | 1 |
| 2027 | $-0.55 | $-0.55 – $-0.55 | $5.8M | $5.8M – $5.8M | 1 |
| 2028 | $-0.49 | $-0.49 – $-0.49 | $5M | $5M – $5M | 1 |
| 2029 | $-1.37 | $-1.37 – $-1.37 | $17.45M | $17.45M – $17.45M | 1 |
